Trial reportInternational journal of molecular sciences2021
A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity.
Trial report in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.Diabetes, obesity & metabolism · 2025Trial
- Sodium R-lipoate protects against psoriatic skin inflammation via modulating IL-23/IL-17A axis, oxidative stress, and mast cell activation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Visceral, Not Abdominal Subcutaneous, Fat Cell Size Associates with Metabolic Dysfunction-Associated Liver Disease in Severe Obesity.Obesity facts · 2026Article
- Is Adipose Tissue Inflammation the Culprit of Obesity-Associated Comorbidities?Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.Signal transduction and targeted therapy · 2025Review
- White adipose tissue browning and peroxisome proliferator activated receptors in MASLD.Frontiers in endocrinology · 2025Review
- Relationship between albumin-corrected anion gap and non-alcoholic fatty liver disease: a cross-sectional analysis of NHANES 2017-2018.Frontiers in medicine · 2025Article
- Synergistic impact of Composite Dietary Antioxidant Index and physical activity on fatty liver disease.Frontiers in nutrition · 2024Article
- The vascular endothelial growth factor system-a new player in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.Hepatobiliary surgery and nutrition · 2023Article
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation.International journal of molecular sciences · 2023Review
- Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease.EBioMedicine · 2023Article
- What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).Journal of clinical medicine · 2023Review
- Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.Frontiers in pharmacology · 2023Review
- Visceral Adipose Tissue Molecular Networks and Regulatory microRNA in Pediatric Obesity: An In Silico Approach.International journal of molecular sciences · 2022Article
- Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity.International journal of molecular sciences · 2022Article
- Biological Determinants of Metabolic Syndrome in Visceral and Subcutaneous Adipose Tissue from Severely Obese Women.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Development and severity of nonalcoholic fatty liver disease (NAFLD) have been linked to obesity and white adipose tissue (WAT) dysfunction plays a key role in this relation. We compared the main features of subcutaneous (SAT) and visceral WAT (VAT) tissue dysfunction in 48 obese women without (Ob) and with NAFLD (Ob-NAFLD) undergoing bariatric surgery and matched for age, BMI and T2D status. Fat cell area, adipocyte size distribution, the degree of histological fibrosis and the mRNA expression of adipokines and genes implicated in inflammation, adipogenesis, angiogenesis, metabolism and extracellular matrix remodeling were measured by RT-qPCR in both fat depots. Ob-NAFLD group showed higher TG and lower HDL circulating levels, increased VAT fat cell area and similar WAT fibrosis in comparison with Ob group. A sPLS-DA was performed in order to identify the set of genes that better characterize the presence of NAFLD. Finally, we build a multinomial logistic model including seven genes that explained 100% of the variance in NAFLD and correctly predicted 100% of cases. Our data support the existence of distinctive NAFLD signatures in WAT from women with severe obesity. A better understanding of these pathways may help in future strategies for the prevention and treatment of NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.